High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 309-316

  Gubbels, Marc Jan ^a   Li, Catherine ^a   Striepen, Boris ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; CYTOCHALASIN D; GENOMIC DNA; PYRIMETHAMINE; YELLOW FLUORESCENT PROTEIN;

ARTICLE; FLUORESCENCE; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NONHUMAN; PARASITE; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 0037228729     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.309-316.2003     Document Type: Article

References (47)

1. Beckers, C. J., D. S. Roos, R. G. Donald, B. J. Luft, J. C. Schwab, Y. Cao, and K. A. Joiner. 1995. Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. J. Clin. Investig. 95:367-376.
2. Burg, J. L., D. Perelman, L. H. Kasper, P. L. Ware, and J. C. Boothroyd. 1988. Molecular analysis of the gene encoding the major surface antigen of Toxoplasma gondii. J. Immunol. 141:3584-3591.
3. Caldwell, J. E., T. Heier, P. M. Wright, S. Lin, G. McCarthy, J. Szenohbradszky, M. L. Sharma, J. P. Hing, M. Schroeder, and D. I. Sessler. 2000. Temperature-dependent pharmokinetics and pharmacodynamics of vecuronium. Anesthesiology 92:84-93.
4. Camps, M., G. Arrizabalaga, and J. Boothroyd. 2002. An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii. Mol. Microbiol. 43:1309-1318.
5. Cubitt, A. B., L. A. Woollenweber, and R. Heim. 1999. Understanding structure-function relationships in the Aequorea victoria green fluorescent protein. Methods Cell Biol. 58:19-30.
6. Derouin, F., and C. Chastang. 1988. Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture. Antimicrob. Agents Chemother. 32:303-307.
7. Desmonts, G., and J. Couvreur. 1974. Congenital toxoplasmosis. A prospective study of 378 pregnancies. N. Engl. J. Med. 290:1110-1116.
8. Dobrowolski, J. M., and L. D. Sibley. 1996. Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. Cell 84:933-939.
9. Donald, R. G. K., and D. S. Roos. 1993. Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistant mutations in malaria. Proc. Natl. Acad. Sci. USA 90:11703-11707.
10. Donald, R. G. K., D. Carter, B. Ullman, and D. S. Roos. 1996. Insertional tagging, cloning, and expression of the Toxoplasma gondii hypoxanthinexanthine-guanine phosphoribosyltransferase gene. Use as a selectable marker for stable transformation. J. Biol. Chem. 271:14010-14019.
11. Fichera, M. E., and D. S. Roos. 1997. A plastid organelle as a drug target in apicomplexan parasites. Nature 390:407-409.
12. Fichera, M. E., M. K. Bhopale, and D. S. Roos. 1995. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob. Agents Chemother. 39:1530-1537.
13. Frenkel, J. K., R. W. Weber, and M. N. Lunde. 1960. Acute toxoplasmosis. Effective treatment with pyrimethamine, sulfadiazine, leucovorin calcium and yeast. JAMA 173:1471-1476.
14. Gay-Andrieu, F., G. J. N. Cozon, J. Ferrandiz, S. Kahl, and F. Peyron. 1999. Flow cytometric quantification of Toxoplasma gondii cellular infection and replication. J. Parasitol. 85:545-549.
15. Georgiev, V. S. 1994. Management of toxoplasmosis. Drugs 48:179-188.
16. Gervaix, A., D. West, L. M. Leoni, D. D. Richman, F. Wong-Staal, and J. Corbeil. 1997. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc. Natl. Acad. Sci. USA 94:4653-4658.
17. Hu, K., D. S. Roos, and J. M. Murray. 2002. A novel polymer of tubulin forms the conoid of Toxoplasma gondii. J. Cell Biol. 156:1039-1050.
18. Hu, K., T. Mann, B. Striepen, C. J. Beckers, D. S. Roos, and J. M. Murray. 2002. Daughter cell assembly in the protozoan parasite Toxoplasma gondii. Mol. Biol. Cell 13:593-606.
19. Kamau, S. W., F. Grimm, and A. B. Hehl. 2001. Expression of green fluorescent protein as a marker for effect of antileishmanial compounds in vitro. Antimicrob. Agents Chemother. 45:3654-3656.
20. Kim, K., D. Soldati, and J. C. Boothroyd. 1993. Gene replacement in Toxoplasma gondii with chloramphenicol acetyltransferase as selectable marker. Science 262:911-914.
21. Knoll, L. J., G. L. Furie, and J. C. Boothroyd. 2001. Adaptation of signaturetagged mutagenesis for Toxoplasma gondii: a negative screening strategy to isolate genes that are essential in restrictive growth conditions. Mol. Biochem. Parasitol. 116:11-16.
22. Leport, C., F. Raffi, S. Matheron, C. Katlama, B. Regnier, A. G. Salmot, C. Vedrenne, and J. L. Vilde. 1988. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am. J. Med. 84:94-100.
23. Luft, B. J., and J. S. Remington. 1992. Toxoplasmic encephalitis in AIDS. Clin. Infect. Dis. 15:211-222.
24. Mamidi, A., J. A. DeSimone, and R. J. Pomerantz. 2002. Central nervous system infections in individuals with HIV-1 infection. J. Neurovirol. 8:158-167.
25. McFadden, D. C., F. Seeber, and J. C. Boothroyd. 1997. Use of Toxoplasma gondii expressing β-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob. Agents Chemother. 41:1849-1853.
26. Merli, A., A. Canessa, and G. Melioli. 1985. Enzyme immunoassay for evaluation of Toxoplasma gondii growth in tissue culture. J. Clin. Microbiol. 21:88-91.
27. Nare, B., J. J. Allocco, P. A. Liberator, and R. G. Donald. 2002. Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy. Antimicrob. Agents Chemother. 46:300-307.
28. Patterson, G., R. N. Day, and D. Piston. 2001. Fluorescent protein spectra. J. Cell Sci. 114:837-838.
29. Pelletier, L., C. A. Stern, M. Pypaert, D. Sheff, H. M. Ngo, N. Roper, C. Y. He, K. Hu, D. Toomre, I. Coppens, D. S. Roos, K. A. Joiner, and G. Warren. 2002. Golgi biogenesis in Toxoplasma gondii. Nature 418:548-552.
30. Pfefferkorn, E. R., and L. C. Pfefferkorn. 1977. Specific labeling of intracellular Toxoplasma gondii with uracil. J. Protozool. 24:449-453.
31. Remington, J. S., R. McLeod, and G. Desmonts. 1995. Toxoplasmosis, p. 140-267. In J. S. Remington and J. O. Klein (ed.), Infectious diseases of the fetus and newborn infant. Saunders, Philadelphia, Pa.
32. Roos, D. S. 1993. Primary structure of the dihydrofolate reductase-thymidylate synthase gene from Toxoplasma gondii. J. Biol. Chem. 268:6269-6280.
33. Roos, D. S., R. G. K. Donald, N. S. Morrissette, and A. L. C. Moulton. 1994. Molecular tools for genetic dissection of the protozoan parasite Toxoplasma gondii. Methods Cell Biol. 45:27-63.
34. Santos-Filho, O. A., R. K. Mishra, and A. J. Hopfinger. 2001. Free energy force field (FEFF) 3D-QSAR analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors. J. Comput. Aided Mol. Des. 15:787-810.
35. Schulz, C. S., R. P. Salvatici, D. J. Standen, M. E. Cabeza, and R. G. Carpentier. 1998. Temperature-dependent inotropic effect of lignocaine and ethanol on the rat heart papillary muscles. Clin. Exp. Pharmacol. Physiol. 25:913-918.
36. Soldati, D., and J. C. Boothroyd. 1993. Transient transfection and expression in the obligate intracellular parasite Toxoplasma gondii. Science 260:349-352.
37. Steff, A.-M., M. Fortin, C. Arguin, and P. Hugo. 2001. Detection of decrease in green fluorescent protein fluorescence for the monitoring of cell death: an assay amendable to high-throughput screening technologies. Cytometry 45:237-243.
38. Striepen, B., C. Y. He, M. Matrajt, D. Soldati, and D. S. Roos. 1998. Expression, selection, and organellar targeting of the green fluorescent protein in Toxoplasma gondii. Mol. Biochem. Parasitol. 92:325-338.
39. Striepen, B., D. Soldati, N. Garcia-Reguet, J. F. Dubremetz, and D. S. Roos. 2001. Targeting of soluble proteins to the rhoptries and micronemes in Toxoplasma gondii. Mol. Biochem. Parasitol. 113:45-53.
40. Striepen, B., M. J. Crawford, M. K. Shaw, L. G. Tilney, F. Seeber, and D. S. Roos. 2000. The plastid of Toxoplasma gondii is divided by association with the centrosomes. J. Cell Biol. 151:1423-1434.
41. Striepen, B., M. W. White, C. Li, M. N. Guerini, S. B. Malik, J. M. Logsdon, Jr., C. Liu, and M. S. Abrahamsen. 2002. Genetic complementation in apicomplexan parasites. Proc. Natl. Acad. Sci. USA 99:6304-6309.
42. Tomavo, S., and J. C. Boothroyd. 1995. Interconnection between organellar functions, development and drug resistance in the protozoan parasite, Toxoplasma gondii. Int. J. Parasitol. 25:1293-1299.
43. Tsien, R. Y. 1998. The green fluorescent protein. Annu. Rev. Biochem. 67:509-544.
44. Winstanley, P. 2001. Modern chemotherapeutic options for malaria. Lancet Infect. Dis. 1:242-250.
45. Wong, S. Y., and J. S. Remington. 1993. Biology of Toxoplasma gondii. AIDS 7:299-316.
46. Zafer, A. A., Y. E. Taylor, and S. A. Sattar. 2001. Rapid screening method for mycobactericidal activity of chemical germicides that uses Mycobacterium terrae expressing a green fluorescent protein gene. Appl. Environ. Microbiol. 67:1239-1245.
47. Zhu, M., and W. E. Fahl. 2000. Development of a green fluorescent protein microplate assay for the screening of chemopreventive agents. Anal. Biochem. 287:210-217.